HonCode

Go Back   HER2 Support Group Forums > Breast Cancer News
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-28-2010, 01:54 PM   #1
1rarebird
Senior Member
 
Join Date: Feb 2010
Location: TN
Posts: 175
Encouraging Bisphosphonates Report

Curr Opin Rheumatol. 2010 May 13. [Epub ahead of print]
Bisphosphonate adverse effects, lessons from large databases.

Abrahamsen B.
aCopenhagen University Hospital Gentofte, Department of Medicine Internal Medicine and Endocrinology F, Niels Andersensvej 65, DK-2900 Hellerup, Denmark bUniversity of Southern Denmark, Institute of Clinical Research, Odense Patient Data Exploratory Network (OPEN), Winslowparken 16, 3., DK-5000 Odense C, Denmark.
Abstract

PURPOSE OF REVIEW: To review the latest findings on bisphosphonate safety from health databases, in particular sources that can provide incidence rates for stress fractures, osteonecrosis of the jaw (ONJ), atrial fibrillation and gastrointestinal lesions including esophageal cancer. The main focus is on bisphosphonates used for osteoporosis. RECENT FINDINGS: Register studies have so far not confirmed a shift from classical to nonclassical femur fractures with bisphosphonates. However, studies were either small or without X-ray adjudication. Two new studies found no increase in jaw surgery for inflammatory conditions - a proxy for ONJ - with oral bisphosphonates, but the risk of jaw necrosis was increased almost eight times in those receiving i.v. bisphosphonates. The risk of atrial fibrillation with alendronate may be increased in the first weeks of treatment, but no excess risk was seen in long-term users. Two studies have found decreased risk of esophageal cancer in patients taking oral bisphosphonates. SUMMARY: Compared with the reduction in classical osteoporotic fractures, the risk of harm caused by bisphosphonates is low, according to information presently available from clinical trials and from health databases. However, database studies have limited specificity and sensitivity for atypical fractures and ONJ. Clinical case control studies are recommended.
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
1rarebird is offline   Reply With Quote
Old 05-29-2010, 11:04 AM   #2
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Re: Encouraging Bisphosphonates Report

I hope the positive news continues and that ONJ can be dealt with/avoided in future.
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:46 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter